hepatocellular-carcinoma

Documents about hepatocellular-carcinoma

• In Vitro Models of Liver and Pancreatic Cancer#855871ClinicalTrials.gov
• Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy#856204ClinicalTrials.gov
• Anatomical Right Posterior Sectionectomy of the Liver by IOUS-Guided Finger Compression#875323ClinicalTrials.gov
• Radiomics for Diagnosing Liver Diseases and Evaluating Progression#876429ClinicalTrials.gov
• Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere#885720ClinicalTrials.gov
• Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Liver Cancer Receiving Transarterial Chemoembolization With Drug Eluting Beads#886073ClinicalTrials.gov
• Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program#802496ClinicalTrials.gov
• Clinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab#274199HAL (France)
• α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma#340177IRIS
• HN1-mediated activation of lipogenesis through Akt-SREBP signaling promotes hepatocellular carcinoma cell proliferation and metastasis#342290KOASAS: KAIST Open Access Self-Archiving System
• Table 3_Integrated multi-omics analysis of metabolomics and proteomics uncovers dysregulated amino acid metabolism in HCC metastasis.xls#464150Figshare
• Table 1_Integrated multi-omics analysis of metabolomics and proteomics uncovers dysregulated amino acid metabolism in HCC metastasis.docx#464151Figshare
• Table 2_Integrated multi-omics analysis of metabolomics and proteomics uncovers dysregulated amino acid metabolism in HCC metastasis.xlsx#464152Figshare
• Image 5_Integrated multi-omics analysis of metabolomics and proteomics uncovers dysregulated amino acid metabolism in HCC metastasis.jpeg#464154Figshare
• Image 4_Integrated multi-omics analysis of metabolomics and proteomics uncovers dysregulated amino acid metabolism in HCC metastasis.jpeg#464155Figshare
• Image 2_Integrated multi-omics analysis of metabolomics and proteomics uncovers dysregulated amino acid metabolism in HCC metastasis.jpeg#464156Figshare
• Image 3_Integrated multi-omics analysis of metabolomics and proteomics uncovers dysregulated amino acid metabolism in HCC metastasis.jpeg#464157Figshare
• Image 1_Integrated multi-omics analysis of metabolomics and proteomics uncovers dysregulated amino acid metabolism in HCC metastasis.jpeg#464158Figshare
• Astragaloside IV and rapamycin co-loaded bone marrow mesenchymal stem cell-derived exosome nanocarriers for targeted modulation of the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.#645444NCBI PubMed Central
• Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies#804732ClinicalTrials.gov
• HAIC Combined With Adebrelimab Plus Apatinib as the First-line Treatment for HCC in BCLC Stage C: An Open-label, Single-arm, Phase II Study#827023ClinicalTrials.gov
• Evaluation the Growth Factors(IGF-1,IGFBP-3and HGH)in Patients With Chronic Liver Disease#866846ClinicalTrials.gov
• NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors#877362ClinicalTrials.gov
• A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC#898608ClinicalTrials.gov
• Auxiliary Diagnosis of Liver Nodules Using cfDNA Whole-genome Signatures#905103ClinicalTrials.gov
• Survival outcomes of intensity-modulated radiotherapy combined with immunotherapy and targeted therapy for hepatocellular carcinoma with classification I-IV portal vein tumor thrombus: a propensity score matching study.#449939NCBI PubMed Central
• HAIC-Based versus TACE-Based Triple Therapy with Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective Propensity Score-Matched Study.#481055NCBI PubMed Central
• Integrated computational analysis prioritizes candidate targets and pathways linking ochratoxin A exposure to hepatocellular carcinoma#626379PLOS
• Contrast Enhanced (CE) Ultrasound and CE Computed Tomography or CE Magnetic Resonance Imaging in Liver Masses#812851ClinicalTrials.gov
• Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis#832500ClinicalTrials.gov
• Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry)#833700ClinicalTrials.gov
• Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NEN#845517ClinicalTrials.gov
• An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer#849852ClinicalTrials.gov
• Italian Study Of Validation Of Angiogenesis Polymorphisms In HCC Patients Treated With Sorafenib#854937ClinicalTrials.gov
• Parenchyma Resection of Cirrhotic Liver by the Clamp Crushing Technique and the Ultrasonic Dissector#913054ClinicalTrials.gov
• 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors#881267ClinicalTrials.gov
• Spatial transcriptomic-metabolic features of tumor foci and tumor capsule in microvascular invasion with hepatocellular carcinoma: A spatial multi-omics study#187818PLOS
• Cost-effectiveness analysis of anlotinib plus penpulimab as first-line treatment for unresectable hepatocellular carcinoma#460274Figshare
• Neutrophil Extracellular Traps as a Biomarker to Predict Portal Vein Tumor Thrombosis in Patients With Hepatocellular Carcinoma#849652ClinicalTrials.gov
• HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B#862772ClinicalTrials.gov
• HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC#912416ClinicalTrials.gov
• A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies#417550ClinicalTrials.gov
• The Yin-yang of HCC management: Reconciling therapeutic hierarchy and transplant benefit in Real-World evidence#449012IRIS
• Clinical Outcomes of HBeAg-negative CHB Patients With Indeterminate Phase#805637ClinicalTrials.gov
• Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant#810951ClinicalTrials.gov
• Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer#833931ClinicalTrials.gov
• A Prototype AI Algorithm Versus Liver Imaging Reporting and Data System (LI-RADS) Criteria in Diagnosing HCC on CT#892108ClinicalTrials.gov
• Neutralization of the autophagy-repressive tissue hormone DBI/ACBP (diazepam binding inhibitor, acyl-CoA binding protein) for the treatment of hepatocellular carcinoma#652790HAL (France)
• CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome#908699ClinicalTrials.gov
• A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer#125848ClinicalTrials.gov